GSK Agrees to Buy Nuvalent for $10.6 Billion in Oncology Push

GSK has agreed to acquire U.S. biotechnology company Nuvalent for $10.6 billion, after earlier reports said the two companies were in talks over a deal worth more than $9 billion.

The acquisition gives GSK three drug candidates for lung cancer and other assets to support its oncology pipeline. Two of the lung cancer drugs are currently under review by the U.S. Food and Drug Administration for approval this year.

GSK said the deal is expected to add to revenue growth from 2027 and be accretive to core operating profit in 2027 and core earnings per share in 2029, including synergies and reprioritisation. The company described the purchase as part of its push in cancer treatments.

GSK agreed to buy Nuvalent, a U.S.-based biotechnology company focused on cancer drugs.

The deal is valued at $10.6 billion.

GSK said the deal will strengthen its oncology pipeline by adding three lung cancer drug candidates and other assets.

Yes. Two of the lung cancer drug candidates are under review by the FDA this year.

Reuters

UK pharmaceutical group GSK ‌is in talks to buy cancer ⁠drugmaker Nuvalent for more than $9 billion, the Financial Times reported ‌on ⁠Monday, citing people familiar with the ⁠matter.

CNBC

UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of finalizing a deal as early as this week.

Reuters

British drugmaker ‌GSK on Tuesday ⁠agreed to acquire U.S.-listed cancer drug ‌developer ⁠Nuvalent for $10.6 billion.

Proactive Investors

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire US biotechnology company Nuvalent for $10.6 billion (£8.0 billion), adding "immediate" new sales growth opportunities, as well as a trio of advanced lung cancer drugs and other assets to boost its oncology pipeline. The FTSE 100 pharmaceuticals group...

WSJ

The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.

Market Watch

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

Invezz

The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal valued at $10.6 billion. By 0810 GMT, the blue-chip FTSE 100 had slipped 0.3% to 10,341 points.

Barrons

GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.

Invezz

GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio. The acquisition,...

Schaeffers Research

Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion.

Business Wire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Nuvalent, Inc. (NASDAQ: NUVL) to GSK plc for $124.00 per share in cash. Halper Sadeh encourages Nuvalent shareholders to click here to learn more about their rights and options or contact Daniel Sa...

Investors Business Daily

Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.

Schwab Network

Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) price target to $140 from $115, and GSK's (GSK) new $10.6 billon acquisition of Nuvalent (NUVL).

GlobeNewsWire

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is...

Zacks Investment Research

GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.

WSJ

After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.

Proactive Investors

GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense. The debate is less about whether the deal is strategically sound and more about how much upside remains after shell...

PRNewsWire

MILWAUKEE, June 10, 2026 /PRNewswire/ -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or c...

Business Wire

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shar...

Reuters

GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca and Roche.

Show All Sources